https://glceducation.com/specialties/nephrology/treatment-considerations-for-pediatric-patients-with-fsgs/37189/daily0.7https://glceducation.com/specialties/oncology/MOA-cdh6-targeted-antibody-drug-conjugates/37668/daily0.7https://glceducation.com/specialties/oncology/clinical-evidence-insights-from-early-trials-of-cdh6-targeted-therapies/37669/daily0.7https://glceducation.com/specialties/nephrology/tbd/37670/daily0.7https://glceducation.com/specialties/nephrology/tbd/37671/daily0.7https://glceducation.com/specialties/nephrology/tbd/37672/daily0.7https://glceducation.com/specialties/nephrology/tbd/37673/daily0.7https://glceducation.com/specialties/nephrology/tbd/37674/daily0.7https://glceducation.com/specialties/nephrology/tbd/37675/daily0.7https://glceducation.com/specialties/nephrology/tbd/37676/daily0.7https://glceducation.com/specialties/ophthalmology/phaco-reloaded-level-up-your-cataract-game/37680/daily0.7https://glceducation.com/specialties/oncology/guideline-recommendations-in-first-line-treatment-of-her2-negative-upper-gi-cancers/37689/daily0.7https://glceducation.com/specialties/oncology/pivotal-data-in-anti-pd-1-strategies-for-her2-negative-upper-gi-cancers/37690/daily0.7https://glceducation.com/specialties/oncology/distinguishing-first-line-treatment-adverse-event-profiles-in-her2-negative-upper-gi-cancers/37691/daily0.7https://glceducation.com/specialties/oncology/quick-case-strategizing-treatment-selection-in-her2-pd-l1-gastric-cancer/37692/daily0.7https://glceducation.com/specialties/ophthalmology/case-discussion-missed-diagnosis/37708/daily0.7https://glceducation.com/specialties/ophthalmology/overcoming-cultural-and-communication-disconnects-part-of-the-focused-sight-initiative-quality-improvement-interventions-in-retinal-disease/37710/daily0.7https://glceducation.com/specialties/ophthalmology/patient-at-high-risk-of-loss-to-follow-up-part-of-the-focused-sight-initiative-quality-improvement-interventions-in-retinal-disease/37711/daily0.7https://glceducation.com/specialties/endocrinology/a-case-of-missed-diagnosis-part-of-the-focused-sight-initiative-quality-improvement-interventions-in-retinal-disease/37713/daily0.7https://glceducation.com/specialties/ophthalmology/it-takes-a-village-part-of-the-focused-sight-initiative-quality-improvement-interventions-in-retinal-disease/37714/daily0.7https://glceducation.com/specialties/oncology/safety-and-tolerability-of-cdh6-directed-antibody-drug-conjugates/37865/daily0.7https://glceducation.com/specialties/oncology/looking-ahead-integrating-cdh6-targeted-therapies-into-ovarian-cancer-treatment-paradigms/37866/daily0.7https://glceducation.com/specialties/dermatology/a-clear-horizon-in-plaque-psoriasis-an-update-on-investigational-oral-therapies/37867/daily0.7https://glceducation.com/specialties/oncology/rethinking-the-therapeutic-targeting-of-b7-h3-in-es-sclc/37876/daily0.7https://glceducation.com/specialties/oncology/emerging-clinical-evidence-for-b7-h3directed-adcs-in-es-sclc-from-wclc-2025/37877/daily0.7https://glceducation.com/specialties/oncology/translating-clinical-data-into-multidisciplinary-practice-for-es-sclc/37878/daily0.7https://glceducation.com/specialties/neurology/diagnostic-and-diagnosis-logistics-navigating-complexity-across-ages/39028/daily0.7https://glceducation.com/specialties/neurology/gmg-patient-stratification-and-antibody-profiling-personalizing-the-disease-lens/39029/daily0.7https://glceducation.com/specialties/neurology/mg-therapeutic-selection-and-monitoring-efficacy-matching-mechanisms-to-patients/39030/daily0.7https://glceducation.com/specialties/gastroenterology/Clearing-the-Brain-Fog-Innovations-in-the-Treatment-and-Management-of-Hepatic-Encephalopathy/39047/daily0.7https://glceducation.com/specialties/gastroenterology/from-flare-to-farewell-the-ibd-care-playbook-for-advanced-practice-providers/39248/daily0.7https://glceducation.com/specialties/hematologyoncology/navigating-treatment-sequencing-after-frontline-treatment-failure-in-cll/39260/daily0.7https://glceducation.com/specialties/hematologyoncology/double-class-refractory-cll-in-community-practice-current-and-future-management/39261/daily0.7https://glceducation.com/specialties/hematologyoncology/personalizing-first-line-therapy-for-cll/39262/daily0.7https://glceducation.com/specialties/gastroenterology/hepatic-encephalopathy-an-ominous-sign/39278/daily0.7https://glceducation.com/specialties/gastroenterology/the-clinical-spectrum-of-hepatic-encephalopathy/39304/daily0.7https://glceducation.com/specialties/oncology/the-tumor-thats-not-so-tiny-understanding-the-impact-of-tgct/39305/daily0.7https://glceducation.com/specialties/infectious-disease/RSV-in-Infants-and-Young-Children-Are-You-Taking-It-Seriously-Enough/39306/daily0.7https://glceducation.com/specialties/infectious-disease/taking-action-against-rsv-no-child-unprotected/39307/daily0.7https://glceducation.com/specialties/gastroenterology/hepatic-encephalopathy-tipping-the-balance/39660/daily0.7https://glceducation.com/specialties/gastroenterology/you-cant-diagnose-mhe-unless-you-diagnose-cirrhosis/39661/daily0.7https://glceducation.com/specialties/gastroenterology/diagnosing-minimal-hepatic-encephalopathy-theres-an-app-for-that/39662/daily0.7https://glceducation.com/specialties/gastroenterology/hepatic-encephalopathy-whats-sarcopenia-got-to-do-with-it/39663/daily0.7https://glceducation.com/specialties/gastroenterology/treatment-of-overt-hepatic-encephalopathy/39664/daily0.7https://glceducation.com/specialties/gastroenterology/hepatic-encephalopathy-unmet-therapeutic-needs/39665/daily0.7https://glceducation.com/specialties/cardiology/victor-prespecified-analysis-results-vericiguat-effects-on-mortality-in-ambulatory-patients-with-hfref/39252/daily0.7https://glceducation.com/specialties/cardiology/victor-trial-results-regional-variation-in-outcomes-and-response-to-vericiguat-in-patients-with-hfref/39249/daily0.7https://glceducation.com/specialties/endocrinology/easd-highlights-prediabetes-diagnosis-prevalence-misclassification-risks-and-the-potential-for-remission/39700/daily0.7https://glceducation.com/specialties/endocrinology/behind-the-screens-innovations-in-type-1-diabetes-clinical-trialsfrom-immunomodulation-to-screening-strategies-and-advanced-cell-therapies/39701/daily0.7https://glceducation.com/specialties/endocrinology/implications-of-the-fine-one-trial-how-might-recently-presented-data-from-the-2025-kidney-meeting-influence-the-current-treatment-paradigm-for-type-1-diabetes-and-ckd/39958/daily0.7https://glceducation.com/specialties/oncology/cohort-9-of-the-phase-2-ev-202-trial-first-line-enfortumab-vedotin-plus-pembrolizumab-in-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma/39779/daily0.7https://glceducation.com/specialties/gastroenterology/Hepatic-Encephalopathy-More-Common-Than-You-Think/39786/daily0.7https://glceducation.com/specialties/gastroenterology/Minimal-Hepatic-Encephalopathy-Hiding-in-Plain-Sight/39787/daily0.7https://glceducation.com/specialties/gastroenterology/Minimal-Hepatic-Encephalopathy-A-Covert-Operation/39788/daily0.7https://glceducation.com/specialties/gastroenterology/The-Slippery-Slope-of-Overt-Hepatic-Encephalopathy/39789/daily0.7https://glceducation.com/specialties/gastroenterology/Treatment-of-Hepatic-Encephalopathy-When-What-How-and-Why/39790/daily0.7https://glceducation.com/specialties/gastroenterology/Treatment-of-Hepatic-Encephalopathy-Primary-vs-Secondary-Prophylaxis/39791/daily0.7https://glceducation.com/specialties/gastroenterology/Optimizing-Care-of-the-Hospitalized-Patient-With-Overt-Hepatic-Encephalopathy/39792/daily0.7https://glceducation.com/specialties/gastroenterology/Current-Treatment-of-Hepatic-Encephalopathy-Is-It-Meeting-Our-Patients-Needs/39793/daily0.7https://glceducation.com/specialties/cardiology/advances-in-the-oreatment-of-overt-hepatic-encephalopathy-whats-in-the-pipeline/39794/daily0.7https://glceducation.com/specialties/oncology/routes-reconsidered-a-case-based-debate-in-serd-selection/39807/daily0.7https://glceducation.com/live-events/redefining-gmg-management-fcrn-antagonists-and-the-new-era-of-precision-neurology/45567/daily0.7https://glceducation.com/specialties/oncology/chairpersons-perspective-evidence-informed-clinical-decision-making-in-her2-overexpressed-and-trop2-targeted-nsclc/39894/daily0.7https://glceducation.com/specialties/ophthalmology/Signaling-for-Sustained-Change-Spotlight-on-the-Potential-of-TKIs-to-Deliver-Durable-Control-of-Exudative-Retinal-Disease/39934/daily0.7https://glceducation.com/specialties/dermatology/when-topicals-fail-the-new-ipc-consensus-every-clinician-should-know/39967/daily0.7https://glceducation.com/specialties/oncology/clinical-criteria-and-imaging-strategies-for-b7-h3directed-adcs-in-es-sclc/39977/daily0.7https://glceducation.com/specialties/oncology/emerging-clinical-evidence-for-b7-h3directed-adcs-in-es-sclc-from-esmo-2025/39978/daily0.7https://glceducation.com/specialties/oncology/clinical-implications-of-emerging-data-on-b7-h3directed-adcs-in-the-future-of-es-sclc/39979/daily0.7https://glceducation.com/specialties/neurology/treat-target-transform-applying-treat-to-target-principles-in-the-management-of-generalized-myasthenia-gravis-gmg/39980/daily0.7https://glceducation.com/specialties/oncology/adjuvant-pembrolizumab-plus-cisplatin-based-chemoradiation-in-locally-advanced-hnscc-first-results-from-the-randomized-phase-2b-adrisk-trial/39706/daily0.7https://glceducation.com/specialties/cardiology/global-burden-of-stroke-and-myocardial-infarction-in-patients-at-high-risk-of-first-mace-insights-from-the-vesalius-real-study/39990/daily0.7https://glceducation.com/specialties/oncology/amivantamab-monotherapy-or-in-combination-with-paclitaxel-in-previously-treated-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-origami-4-study-results/39780/daily0.7https://glceducation.com/specialties/oncology/patient-reported-outcomes-from-the-phase-3-keynote-689-trial-of-adding-perioperative-pembrolizumab-to-standard-of-care-in-resectable-locally-advanced-hnscc/39777/daily0.7https://glceducation.com/specialties/oncology/keynote-717-randomized-phase-2-trial-of-adding-local-hypofractionated-radiotherapy-to-pembrolizumab-in-recurrent-or-metastatic-head-and-neck-cancer/39778/daily0.7https://glceducation.com/specialties/cardiology/earlier-action-lasting-impact-closing-the-ldl-c-gap-in-patients-without-a-prior-mace/39957/daily0.7https://glceducation.com/specialties/cardiology/the-overlooked-valve-why-women-with-aortic-stenosis-fall-through-the-cracks/39668/daily0.7https://glceducation.com/specialties/cardiology/advancing-care-for-women-with-aortic-stenosis-2-year-outcomes-for-women-in-the-5-year-smart-trial/39669/daily0.7https://glceducation.com/specialties/cardiology/sotagliflozin-in-hfpef-without-diabetes-inside-the-sota-p-cardia-trial-from-aha-2025/39898/daily0.7https://glceducation.com/specialties/cardiology/real-world-impact-of-evolocumab-on-mace-reduction-in-ascvd/39991/daily0.7https://glceducation.com/specialties/nephrology/new-data-from-the-confidence-trial-the-effect-of-combination-empagliflozin-and-finerenone-on-uacr-and-egfr-in-ckd-and-type-2-diabetes/39959/daily0.7https://glceducation.com/specialties/nephrology/the-impact-of-finerenone-plus-empagliflozin-on-hyperkalemia-in-the-confidence-trial/39960/daily0.7https://glceducation.com/specialties/cardiology/from-pixels-to-practice-advancing-hcm-care-with-multimodality-imaging/39877/daily0.7https://glceducation.com/specialties/oncology/spotlight-on-europe-adapting-the-evidence/39808/daily0.7https://glceducation.com/specialties/oncology/breaking-down-the-benchmarks-pivotal-data-on-first-line-cdk46-inhibitors/39798/daily0.7https://glceducation.com/specialties/oncology/spotlight-on-asia-pacific-practice-beyond-borders/39810/daily0.7https://glceducation.com/specialties/oncology/unmet-needs-in-endocrine-therapy-rethinking-the-hrher2-mbc-treatment-roadmap/39797/daily0.7https://glceducation.com/specialties/nephrology/ckd-ap-oltre-la-superficie/48752/daily0.7https://glceducation.com/specialties/nephrology/quantificare-il-ckd-ap-strumenti-per-una-cura-migliore/48753/daily0.7https://glceducation.com/specialties/nephrology/ckd-ap-o-altro-decodificare-la-diagnosi/48754/daily0.7https://glceducation.com/specialties/nephrology/kit-di-strumenti-terapeutici-per-il-ckd-ap/48755/daily0.7https://glceducation.com/specialties/nephrology/migliorare-lassistenza-per-il-ckd-ap-nuova-frontiera/48756/daily0.7https://glceducation.com/specialties/nephrology/nel-tuo-centro-dialisi-il-ckd-ap-rimane-in-ombra/48757/daily0.7https://glceducation.com/specialties/nephrology/impostazioni-oppioidi-kappa-approfondimenti-sulle-prove-concrete-rwe/48758/daily0.7https://glceducation.com/specialties/nephrology/migliorare-il-sonno-e-la-salute-mentale-nei-pazienti-con-ckd-ap/48759/daily0.7https://glceducation.com/specialties/nephrology/il-rapporto-paziente-medico-nella-gestione-del-ckd-ap/48760/daily0.7https://glceducation.com/specialties/cardiology/the-ambulatory-hfref-blind-spot-proactively-reducing-cv-mortality-risk-despite-optimized-gdmt/48810/daily0.7https://glceducation.com/specialties/cardiology/gdmt-is-working-fine-so-why-add-more-therapies-for-patients-with-hfref/48811/daily0.7https://glceducation.com/specialties/cardiology/missing-the-window-in-ambulatory-patients-with-hfref-on-gdmt-strategies-for-cv-risk-reduction/48813/daily0.7https://glceducation.com/specialties/nephrology/inside-the-4-hits-targeting-april-to-change-the-course-of-igan/48815/daily0.7https://glceducation.com/specialties/nephrology/pa-mrc-au-dela-de-la-surface/48818/daily0.7https://glceducation.com/specialties/nephrology/quantification-du-pa-mrc-des-outils-pour-ameliorer-les-soins/48819/daily0.7https://glceducation.com/specialties/nephrology/pa-mrc-ou-autre-chose-decoder-le-diagnostic/48820/daily0.7https://glceducation.com/specialties/nephrology/boite-a-outils-du-traitement-du-pa-mrc/48821/daily0.7https://glceducation.com/specialties/nephrology/ameliorer-les-soins-du-pa-mrc-de-nouvelles-frontieres/48822/daily0.7https://glceducation.com/specialties/nephrology/le-pa-mrc-se-cache-t-il-dans-votre-centre-de-dialyse/48823/daily0.7https://glceducation.com/specialties/nephrology/contextes-des-recepteurs-opioides-kappa-perspectives-issues-des-donnees-du-monde-reel/48824/daily0.7https://glceducation.com/specialties/nephrology/ameliorer-le-sommeil-et-la-sante-mentale-des-patients-atteints-de-pa-mrc/48825/daily0.7https://glceducation.com/specialties/nephrology/la-relation-patient-clinicien-dans-la-prise-en-charge-du-pa-mrc/48826/daily0.7https://glceducation.com/specialties/hematologyoncology/precision-strikes-in-aml-navigating-the-evolving-landscape-of-targeted-therapies/48856/daily0.7https://glceducation.com/live-events/reframing-igan-care-patient-centered-strategies-to-curb-proteinuria-and-preserve-kidney-function/48830/daily0.7https://glceducation.com/live-events/advancing-patient-centered-guideline-driven-management-of-hyperkalemia-in-adults-with-ckd-and-associated-comorbidities/48831/daily0.7https://glceducation.com/specialties/cardiology/adapt-af-des-antithrombotic-strategies-beyond-12-months-for-patients-with-af-treated-with-drug-eluting-stents/48694/daily0.7https://glceducation.com/specialties/cardiology/poly-hf-trial-a-polypill-strategy-for-heart-failure-with-reduced-ejection-fraction-hfref/48691/daily0.7https://glceducation.com/specialties/cardiology/decaf-trial-does-eliminating-coffee-reduce-atrial-fibrillation-recurrence-in-symptomatic-patients/48690/daily0.7https://glceducation.com/specialties/cardiology/ocean-trial-at-aha-2025-anticoagulation-after-af-ablation-in-high-risk-patients/48695/daily0.7https://glceducation.com/specialties/cardiology/dare-af-trial-dapagliflozin-to-reduce-af-burden-after-catheter-ablation-in-patients-without-diabetes-or-heart-failure/48682/daily0.7https://glceducation.com/specialties/cardiology/primary-results-of-the-vesalius-cv-trial-evolocumab-in-patients-at-high-cardiovascular-risk-without-prior-mi-or-stroke/45568/daily0.7https://glceducation.com/specialties/oncology/beyond-the-scalpel-when-tgct-surgery-isnt-the-solution/48904/daily0.7https://glceducation.com/specialties/oncology/unlocking-the-csf1r-code-targeted-pathways-and-tailored-choices/48905/daily0.7https://glceducation.com/specialties/oncology/clinical-evidence-in-focus-interpreting-data-on-systemic-therapy-targeting-csf1r/48906/daily0.7https://glceducation.com/specialties/oncology/surgical-crossroads-practical-considerations-for-optimizing-treatment-in-tgct/48907/daily0.7https://glceducation.com/specialties/oncology/applying-the-evidence-tgct-treatment-insights-for-sports-medicine-physicians/48909/daily0.7https://glceducation.com/specialties/oncology/the-safety-equation-managing-adverse-events-associated-with-csf1r-inhibitors-in-tgct/48910/daily0.7https://glceducation.com/specialties/neurology/patient-perspective-navigating-tgct-treatmentsurgery-vs-systemic-therapy/48911/daily0.7https://glceducation.com/specialties/oncology/all-sides-of-the-joint-integrated-tgct-care-across-specialties/48912/daily0.7https://glceducation.com/specialties/ophthalmology/beyond-iop-integrating-ocular-surface-resilience-into-glaucoma-management/49097/daily0.7https://glceducation.com/specialties/cardiology/beyond-steroidal-mras-the-nonsteroidal-mra-lens-in-hf/49198/daily0.7https://glceducation.com/specialties/oncology/Frontline-Insights-Emerging-Therapeutic-Strategies-in-HNSCC/49223/daily0.7https://glceducation.com/specialties/dermatology/calming-overactive-immune-response-and-reducing-inflammation-with-tyk2-inhibition-in-psoriasis/50978/daily0.7https://glceducation.com/specialties/hematologyoncology/advancing-bispecific-antibodies-upstream-in-the-treatment-paradigm-of-multiple-myeloma/49263/daily0.7https://glceducation.com/specialties/hematologyoncology/from-late-line-rescue-to-early-line-option-the-potential-for-bispecific-antibodies-in-multiple-myeloma/49264/daily0.7https://glceducation.com/specialties/hematologyoncology/breaking-the-line-moving-bispecific-antibodies-upstream-in-treating-multiple-myeloma/49265/daily0.7https://glceducation.com/specialties/cardiology/targeting-epicardial-adipose-tissue-in-patients-with-hfpef-without-diabetes-sotagliflozin-effect-from-sota-p-cardia-trial-sub-analysis/49274/daily0.7https://glceducation.com/specialties/dermatology/early-onset-of-response-to-zasocitinib-tak-279-a-highly-selective-and-potent-tyk2-inhibitor-is-correlated-with-modulation-of-tyk2-signaling-and-disease-pathway-biomarkers-in-patients-with-moderate-to-severe-plaque-psoriasis/50977/daily0.7https://glceducation.com/specialties/neurology/scorecards-that-matter-use-mg-adl-mg-mmt-qmg-qol/51034/daily0.7https://glceducation.com/specialties/nephrology/the-4-hit-hypothesis-foundations-of-igan-pathogenesis/51035/daily0.7https://glceducation.com/specialties/neurology/emerging-focus-in-naion-sharpening-diagnostic-precision-for-tomorrows-treatments/49222/daily0.7https://glceducation.com/specialties/gastroenterology/ibd-masterclass-foundations-of-pathophysiology-and-targeted-therapy/49149/daily0.7https://glceducation.com/specialties/cardiology/finerenone-in-ckm-disease-and-hfpef-key-takeaways-from-esc-hf/49255/daily0.7https://glceducation.com/specialties/gastroenterology/ibd-in-focus-a-case-based-approach-to-diagnosis-and-assessment/49150/daily0.7https://glceducation.com/specialties/oncology/emerging-evidence-in-focus-interpreting-data-on-next-generation-csf1r-tkis/48908/daily0.7https://glceducation.com/specialties/cardiology/when-gdmt-isnt-enough-understanding-residual-risk-in-patients-with-hfref/51036/daily0.7https://glceducation.com/specialties/gastroenterology/diagnosing-ibd-is-it-ibd-or-something-else-can-you-tell/51480/daily0.7https://glceducation.com/specialties/gastroenterology/severity-assessment-can-you-pin-the-stage-on-the-patient/51481/daily0.7https://glceducation.com/specialties/gastroenterology/ibd-immunopathogenesis-do-you-know-what-youre-blocking/51482/daily0.7https://glceducation.com/specialties/gastroenterology/tailoring-treatment-can-you-select-the-best-therapy/51483/daily0.7https://glceducation.com/specialties/gastroenterology/case-review-can-you-crack-this-ibd-case/51484/daily0.7https://glceducation.com/specialties/gastroenterology/treat-to-target-are-we-there-yet/51485/daily0.7https://glceducation.com/specialties/gastroenterology/remission-can-you-prove-it/51486/daily0.7https://glceducation.com/specialties/gastroenterology/switching-strategies-switch-or-staywhats-your-call/51487/daily0.7https://glceducation.com/specialties/gastroenterology/case-review-targets-are-metcan-you-stick-the-landing/51488/daily0.7https://glceducation.com/specialties/neurology/The-Struggle-Is-Real/54098/daily0.7https://glceducation.com/specialties/ophthalmology/TKI-The-New-TKO-for-Retinal-Diseases/54099/daily0.7https://glceducation.com/specialties/ophthalmology/To-Implant-or-to-Inject/54100/daily0.7https://glceducation.com/specialties/ophthalmology/Who-Needs-a-TKI-Identifying-the-Right-Candidates/54101/daily0.7https://glceducation.com/specialties/ophthalmology/So-You-Think-You-Want-a-TKI/54102/daily0.7https://glceducation.com/specialties/oncology/early-approaches-to-ras-targeting-efficacy-signals-and-known-limitations/54119/daily0.7https://glceducation.com/specialties/oncology/mechanistic-evolution-in-ras-therapy-on-state-and-multi-selective-targeting/54120/daily0.7https://glceducation.com/specialties/oncology/nsclc-data-review-efficacy-and-safety-data-for-on-state-ras-inhibitors/54121/daily0.7https://glceducation.com/specialties/oncology/evaluating-use-in-pancreatic-cancer-efficacy-and-safety-data-for-on-state-ras-inhibitors/54122/daily0.7https://glceducation.com/specialties/oncology/novel-ras-targeted-therapy-prevention-monitoring-and-mitigation-of-adverse-events/54123/daily0.7https://glceducation.com/specialties/oncology/rason-and-beyond-clinical-integration-and-strategic-sequencing/54124/daily0.7https://glceducation.com/specialties/urology/shifting-the-script-personalizing-overactive-bladder-treatment-in-complex-patients/54125/daily0.7https://glceducation.com/specialties/nephrology/transforming-care-in-pediatric-patients-with-c3-glomerulopathy-targeting-c3-at-the-source/54143/daily0.7https://glceducation.com/specialties/ophthalmology/at-the-lid-line-unmasking-demodex-across-the-osd-spectrum/54261/daily0.7https://glceducation.com/specialties/cardiology/modern-obstructive-hcm-care-from-unmet-needs-to-individualized-myosin-inhibitor-therapy/54306/daily0.7https://glceducation.com/specialties/oncology/navigating-today-and-shaping-tomorrow-in-ism-personalized-strategies-with-current-and-emerging-kit-inhibitors/54388/daily0.7https://glceducation.com/specialties/oncology/The-Future-of-HNSCC-Aligning-Teams-Transforming-Care/54394/daily0.7https://glceducation.com/specialties/cardiology/gdmt-is-working-fine-why-add-more-therapies-the-clinical-rationale-for-layering-therapies-in-patients-with-hfref/54632/daily0.7https://glceducation.com/specialties/cardiology/do-not-delay-timing-triggers-and-identifying-the-right-patient-for-additional-therapies-in-hfref/54633/daily0.7https://glceducation.com/specialties/cardiology/evidence-at-a-glance-the-totality-of-evidence-impacting-clinical-decision-making-in-patients-with-hfref-without-a-recent-worsening-event/54634/daily0.7https://glceducation.com/specialties/cardiology/safety-clinical-integration-and-the-emerging-fifth-pillar-in-hf-practice/54635/daily0.7https://glceducation.com/specialties/nephrology/april-uncovered-an-upstream-driver-in-igan/54680/daily0.7https://glceducation.com/specialties/nephrology/mechanism-based-targeting-why-april-matters-in-igan/54681/daily0.7https://glceducation.com/specialties/nephrology/igan-soc-strengths-and-limits/54682/daily0.7https://glceducation.com/specialties/nephrology/beyond-raasi-and-approved-therapies-the-unmet-needs-in-igan/54683/daily0.7https://glceducation.com/specialties/nephrology/emerging-evidence-igan-disease-modifying-agents/54684/daily0.7https://glceducation.com/specialties/nephrology/emerging-therapies-in-igan-who-could-benefit-the-most/54685/daily0.7https://glceducation.com/specialties/nephrology/targeting-lower-proteinuria-levels-shifting-the-goalpost-in-igan/54686/daily0.7https://glceducation.com/specialties/nephrology/translating-guidelines-to-action-in-igan-embracing-a-simultaneous-dual-concordant-approach/54687/daily0.7https://glceducation.com/specialties/allergy/living-with-systemic-mastocytosis-bridging-clinical-decisions-and-patient-realities/54389/daily0.7https://glceducation.com/specialties/gastroenterology/ibd-beyond-symptoms-what-community-gis-need-to-know/54127/daily0.7https://glceducation.com/specialties/neurology/beyond-the-primary-endpoint-what-oceanic-stroke-subtype-analyses-reveal-about-asundexians-potential/54416/daily0.7https://glceducation.com/specialties/neurology/fxia-remix-keeping-the-flow-without-missing-a-beat/54142/daily0.7https://glceducation.com/specialties/neurology/oceanic-stroke-results-asundexian-for-secondary-stroke-prevention-after-acute-non-cardioembolic-stroke-or-high-risk-tia/54141/daily0.7https://glceducation.com/specialties/oncology/decision-in-context-a-practical-framework-for-sequencing-systemic-and-cns-therapies-in-brain-metastases/54765/daily0.7https://glceducation.com/specialties/oncology/inside-the-decision-case-based-navigation-of-brain-metastases-in-breast-and-lung-cancer/54766/daily0.7https://glceducation.com/specialties/neurology/target-locked-in-gmg-why-t2t-matters/54768/daily0.7https://glceducation.com/specialties/neurology/minimal-by-design-define-mse-endpoints/54769/daily0.7https://glceducation.com/specialties/neurology/turning-flares-into-function-flag-uncontrolled-disease/54770/daily0.7https://glceducation.com/specialties/neurology/when-to-begin-fcrn-initiation-criteria-key-evidence/54771/daily0.7https://glceducation.com/specialties/neurology/the-igg-clock-redose-using-igg-kinetics/54772/daily0.7https://glceducation.com/specialties/neurology/escalate-with-intention-stepwise-target-anchored-moves/54773/daily0.7https://glceducation.com/specialties/neurology/shared-goals-shared-gains-align-with-patient-preferences/54776/daily0.7https://glceducation.com/specialties/neurology/fcrn-same-class-different-pathsspot-agent-differentiators/54778/daily0.7https://glceducation.com/specialties/cardiology/cracking-the-code-of-obstruction-unmet-needs-in-ohcm/54837/daily0.7https://glceducation.com/specialties/cardiology/when-blockers-fall-short-in-ohcm-time-for-a-new-approach/54838/daily0.7https://glceducation.com/specialties/cardiology/molecular-precision-how-myosin-inhibitors-redefine-control/54839/daily0.7https://glceducation.com/live-events/incorporating-novel-muscarinic-agents-for-schizophrenia-into-clinical-practice-overcoming-clinical-inertia/54752/daily0.7https://glceducation.com/specialties/cardiology/primary-care-takeaways-from-vesalius-cv-evolocumab-efficacy-in-patients-without-significant-atherosclerosis/56623/daily0.7https://glceducation.com/specialties/dermatology/once-daily-oral-zasocitinib-demonstrates-rapid-and-reproducible-skin-clearance-with-a-consistent-safety-profile-in-moderate-to-severe-plaque-psoriasis-results-from-two-randomized-phase-3-trials-latitude-pso-3001-and-3002/56617/daily0.7https://glceducation.com/live-events/redefining-gmg-management-fcrn-antagonists-and-the-new-era-of-precision-neurology/56712/daily0.7https://glceducation.com/specialties/ophthalmology/Catching-Demodex-in-the-Act/56703/daily0.7https://glceducation.com/specialties/ophthalmology/At-the-Intersection-of-DB-DED-MGD-and-Other-Forms-of-Blepharitis/56704/daily0.7https://glceducation.com/specialties/ophthalmology/the-missed-diagnosis-a-45-year-old-software-engineer-who-complains-of-dry-eyes/56705/daily0.7https://glceducation.com/specialties/ophthalmology/moving-beyond-lid-hygiene-evidence-based-treatment-strategies/56706/daily0.7https://glceducation.com/specialties/ophthalmology/return-and-revisit-a-38-year-old-patient-returns-for-follow-up-after-lotilaner-treatment/56709/daily0.7https://glceducation.com/specialties/ophthalmology/closing-the-loop-structured-follow-up-and-patient-communication/56708/daily0.7https://glceducation.com/specialties/ophthalmology/Key-Takeaways-and-Practice-Integration/56710/daily0.7https://glceducation.com/specialties/oncology/redefining-immunotherapy-access-integrating-subcutaneous-checkpoint-inhibitors-across-solid-tumors/56117/daily0.7https://glceducation.com/specialties/cardiology/value-of-earlier-lipid-lowering-therapy-intensification-with-evolocumab-in-high-risk-populations-without-known-significant-ascvd-and-with-diabetes-vesalius-cv-insights/56624/daily0.7https://glceducation.com/specialties/oncology/brain-metastases-management-from-detection-to-multidisciplinary-care/56517/daily0.7https://glceducation.com/live-events/22nd-annual-womens-health-annual-visit-whav/56380/daily0.7https://glceducation.com/specialties/cardiology/redefining-ohcm-care-efficacy-and-safety-of-myosin-inhibitors/54840/daily0.7https://glceducation.com/live-events/redefining-gmg-management-fcrn-antagonists-and-the-new-era-of-precision-neurology/56711/daily0.7https://glceducation.com/specialties/cardiology/evolocumab-in-patients-without-significant-atherosclerosis-and-with-diabetes-a-cardiology-perspective-on-vesalius-cv/56744/daily0.7https://glceducation.com/specialties/neurology/the-2-point-signal-apply-2-point-rule/54777/daily0.7https://glceducation.com/live-events/when-mild-matters-most-closing-clinical-gaps-in-early-symptomatic-ad/56353/daily0.7https://glceducation.com/specialties/neurology/from-evidence-to-action-integrating-emerging-myosin-inhibitors-into-ohcm-treatment-plans/54841/daily0.7https://glceducation.com/specialties/neurology/from-beta-blockers-to-myosin-inhibitors-initial-decision-making-in-obstructive-hcm/54843/daily0.7https://glceducation.com/specialties/oncology/her2-breast-cancer-with-brain-metastases-rethinking-first-line-treatment-in-the-adc-era/56518/daily0.7https://glceducation.com/specialties/oncology/first-line-management-of-hrher2-low-breast-cancer-with-brain-metastases/56519/daily0.7https://glceducation.com/specialties/oncology/sequencing-systemic-and-local-therapy-in-her2-overexpressing-metastatic-nsclc/56520/daily0.7https://glceducation.com/specialties/oncology/egfr-mutated-nsclc-with-brain-metastases-navigating-adc-treatment-decisions/56521/daily0.7https://glceducation.com/specialties/oncology/managing-brain-metastases-through-multidisciplinary-team-collaboration/56522/daily0.7https://glceducation.com/live-events/22nd-annual-womens-health-annual-visit-whav/56378/daily0.7https://glceducation.com/specialties/gastroenterology/understanding-the-microbiomes-role-in-ibd-management/56892/daily0.7https://glceducation.com/live-events/incorporating-novel-muscarinic-agents-for-schizophrenia-into-clinical-practice-overcoming-clinical-inertia/56795/daily0.7https://glceducation.com/live-events/clear-skin-clear-path-transforming-psoriasis-care-with-durable-biologic-and-oral-il-23-innovations/56920/daily0.7https://glceducation.com/live-events/clear-skin-clear-path-transforming-psoriasis-care-with-durable-biologic-and-oral-il-23-innovations/56921/daily0.7https://glceducation.com/live-events/data-meets-decision-expert-approaches-to-perioperative-immunotherapy-in-la-hnscc/56983/daily0.7https://glceducation.com/specialties/cardiology/heart-failure-treatment-trends-insights-from-frame-hf-and-iris-hf/57080/daily0.7https://glceducation.com/specialties/cardiology/spirit-hf-does-spironolactone-improve-outcomes-in-hfpef-and-hfmref/57081/daily0.7https://glceducation.com/specialties/ophthalmology/hidden-in-plain-sight-a-modern-guide-to-detecting-and-managing-early-neurotrophic-keratitis/54091/daily0.7https://glceducation.com/specialties/gastroenterology/pathophysiology-of-ibd-the-war-within/56889/daily0.7https://glceducation.com/specialties/gastroenterology/targeting-inflammation-in-ibd-localized-vs-systemic-strategies/56890/daily0.7https://glceducation.com/specialties/neurology/Amyloid-Therapies-in-Practice-Not-All-Are-Created-Equal/56761/daily0.7https://glceducation.com/specialties/gastroenterology/beyond-biology-environmental-and-lifestyle-influences-in-ibd/56891/daily0.7https://glceducation.com/live-events/treating-outside-the-box-new-pathways-to-retinal-vascular-stability/56970/daily0.7https://glceducation.com/specialties/neurology/tau-therapies-and-clinical-translation-mechanistic-approaches/56762/daily0.7https://glceducation.com/specialties/gastroenterology/genetic-susceptibility-in-ibd-from-risk-genes-to-clinical-impact/56893/daily0.7https://glceducation.com/specialties/neurology/nps-psychosis-circuits-treatment-and-new-hope/56765/daily0.7https://glceducation.com/specialties/neurology/nps-agitation-evidence-and-emerging-mechanisms-of-management/56766/daily0.7https://glceducation.com/specialties/neurology/unseen-impact-of-nps-in-ad-domains-and-burden/56764/daily0.7https://glceducation.com/specialties/gastroenterology/putting-it-all-together-challenges-addressed/56894/daily0.7https://glceducation.com/specialties/cardiology/safety-in-ohcm-therapy-how-and-when-to-transition-treatment/56831/daily0.7https://glceducation.com/live-events/data-meets-decision-expert-approaches-to-perioperative-immunotherapy-in-la-hnscc/56984/daily0.7https://glceducation.com/specialties/ophthalmology/VBS-Fellows-Foray-2026-Through-the-Looking-Glass-Real-World-Vitreoretinal-Surgical-Cases/56877/daily0.7https://glceducation.com/live-events/clear-skin-clear-path-transforming-psoriasis-care-with-durable-biologic-and-oral-il-23-innovations/49225/daily0.7https://glceducation.com/specialties/neurology/Beyond-Cognition-Managing-Alzheimers-as-an-Integrated-Neurodegenerative-Neuropsychiatric-Syndrome/54842/daily0.7https://glceducation.com/live-events/translating-evidence-into-practice-patient-centered-guideline-driven-care-in-anca-associated-vasculitis/48829/daily0.7https://glceducation.com/specialties/ophthalmology/the-neverending-journey-a-66-year-old-patient-who-has-undergone-several-rounds-of-tea-tree-oilbased-treatment/56707/daily0.7https://glceducation.com/specialties/oncology/progress-in-breast-cancer-care-translating-sabcs-data-into-practice/48989/daily0.7https://glceducation.com/specialties/neurology/neuroinflammation-to-network-instability-translating-faahmagl-biology-to-nps/56763/daily0.7https://glceducation.com/specialties/oncology/the-new-era-of-ras-targeting-mechanisms-evidence-and-clinical-integration-of-on-state-inhibitors/39770/daily0.7https://glceducation.com/live-events/the-next-generation-of-care-new-treatment-frontiers-in-immunotherapy-resistant-advanced-squamous-nsclc/65283/daily0.7https://glceducation.com/specialties/oncology/advancing-care-in-hnscc-evolving-strategies-across-the-disease-continuum/48999/daily0.7https://glceducation.com/specialties/neurology/modern-obstructive-hcm-care-from-unmet-needs-to-individualized-myosin-inhibitor-therapy/56979/daily0.7https://glceducation.com/specialties/obstetrics-and-gynecology/implementing-the-latest-diagnostic-and-treatment-approaches-for-generalized-myasthenia-gravis/32961/daily0.7https://glceducation.com/live-events/when-mild-matters-most-closing-clinical-gaps-in-early-symptomatic-ad/56354/daily0.7https://glceducation.com/live-events/the-next-generation-of-care-new-treatment-frontiers-in-immunotherapy-resistant-advanced-squamous-nsclc/56402/daily0.7https://glceducation.com/live-events/the-next-generation-of-care-new-treatment-frontiers-in-immunotherapy-resistant-advanced-squamous-nsclc/65354/daily0.7https://glceducation.com/live-events/when-mild-matters-most-closing-clinical-gaps-in-early-symptomatic-ad/56415/daily0.7https://glceducation.com/live-events/when-mild-matters-most-closing-clinical-gaps-in-early-symptomatic-ad/56416/daily0.7https://glceducation.com/specialties/cardiology/no-patient-with-ckd-left-behind-new-horizons-in-patients-with-ckd-regardless-of-diabetes-status/49260/daily0.7https://glceducation.com/live-events/todays-cllsll-decisions-tomorrows-options-practical-strategies-for-the-community-clinic/60601/daily0.7https://glceducation.com/live-events/engineering-safer-antithrombotic-strategies-for-secondary-stroke-prevention/56947/daily0.7https://glceducation.com/live-events/when-mild-matters-most-closing-clinical-gaps-in-early-symptomatic-ad/57171/daily0.7https://glceducation.com/live-events/treatment-decisions-that-matter-live-tumor-board-in-advanced-ovarian-cancer/57214/daily0.7https://glceducation.com/live-events/treatment-decisions-that-matter-live-tumor-board-in-advanced-ovarian-cancer/57215/daily0.7https://glceducation.com/live-events/treatment-decisions-that-matter-live-tumor-board-in-advanced-ovarian-cancer/57216/daily0.7https://glceducation.com/specialties/ophthalmology/retina-rumble-debating-modern-treatment-options/54609/daily0.7https://glceducation.com/live-events/translating-evidence-into-practice-myosin-inhibition-across-the-hcm-spectrum/54342/daily0.7https://glceducation.com/live-events/moving-the-needle-in-ohcm-the-era-of-cardiac-myosin-inhibitors/54823/daily0.7https://glceducation.com/specialties/ophthalmology/enhancing-collaborative-care-in-retinal-diseases-a-focus-on-injection-therapies/37715/daily0.7https://glceducation.com/specialties/nephrology/igan-management-into-practice-evolving-guidelines-targeted-therapies/37238/daily0.7https://glceducation.com/specialties/oncology/spotlight-on-latin-america-closing-the-gap/39809/daily0.7https://glceducation.com/specialties/oncology/safety-of-cdk46-inhibitors-anticipation-prevention-and-management-of-adverse-events/39799/daily0.7https://glceducation.com/specialties/oncology/beyond-fulvestrant-oral-serds-redefining-er-targeting/39800/daily0.7https://glceducation.com/specialties/oncology/the-future-of-oral-serds-combination-strategies/39801/daily0.7https://glceducation.com/specialties/oncology/doublet-or-triplet-a-case-based-debate-in-first-line-choices-for-hrher2-mbc/39806/daily0.7https://glceducation.com/live-events/treating-outside-the-box-new-pathways-to-retinal-vascular-stability/56621/daily0.7https://glceducation.com/specialties/oncology/global-perspectives-on-perioperative-immunotherapy-in-la-hnscc/36261/daily0.7https://glceducation.com/specialties/nephrology/integrating-the-patient-voice-in-fsgs-management/37190/daily0.7https://glceducation.com/specialties/nephrology/future-directions-in-fsgs-care/37191/daily0.7https://glceducation.com/specialties/oncology/optimizing-multidisciplinary-approaches-in-the-guideline-driven-management-of-cervical-and-endometrial-cancers/37236/daily0.7https://glceducation.com/specialties/oncology/from-data-to-debate-global-perspectives-on-hrher2-mbc-care/37268/daily0.7https://glceducation.com/specialties/oncology/Understanding-Endocrine-Resistance-in-HR-HER2-mBC/37323/daily0.7https://glceducation.com/specialties/oncology/PI3K-Pathway-inhibition-in-HR-HER2-mBC-Mechanistic-Insights/37329/daily0.7https://glceducation.com/specialties/oncology/Comprehensive-Biomarker-Testing-in-mBC-Informs-Clinical-Decision-Making/37332/daily0.7https://glceducation.com/specialties/oncology/Double-Take-Pivotal-Data-Evaluating-PI3K-Inhibitor-Endocrine-Therapy-Regimens-in-mBC/37333/daily0.7https://glceducation.com/specialties/oncology/Triple-Threat-Key-Data-on-Simultaneous-Estrogen-CDK4-6-and-PI3K-Inhibition-in-mBC/37335/daily0.7https://glceducation.com/specialties/oncology/Case-in-Point-Applying-PI3K-Combinations-in-Early-Recurrent-HR-HER2-mBC/37336/daily0.7https://glceducation.com/specialties/oncology/PI3K-Pathway-Inhibitors-Safety-and-Tolerability-Profiles/37338/daily0.7https://glceducation.com/specialties/oncology/The-Future-of-PI3K-Inhibition-in-HR-HER2-Breast-Cancer/37339/daily0.7https://glceducation.com/specialties/psychiatry/precision-treatment-pathways-for-mdd-and-comorbid-insomnia/37592/daily0.7https://glceducation.com/specialties/nephrology/stuck-on-antihistamines-for-managing-patients-with-ckd-ap-time-to-reconsider/37607/daily0.7https://glceducation.com/specialties/gastroenterology/hepatic-encephalopathy-an-ominous-sign/39666/daily0.7https://glceducation.com/specialties/cardiology/the-fifth-pillar-closing-the-gap-in-hfref/37615/daily0.7https://glceducation.com/specialties/cardiology/effect-of-vericiguat-on-heart-failure-hospitalization-events-in-ambulatory-patients-with-hfref-victor-trial-prespecified-analysis/37614/daily0.7